Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021:1322:285-312.
doi: 10.1007/978-981-16-0267-2_11.

Covalent Antiviral Agents

Affiliations
Review

Covalent Antiviral Agents

Sako Mirzaie et al. Adv Exp Med Biol. 2021.

Abstract

Nowadays, many viral infections have emerged and are taking a huge toll on human lives globally. Meanwhile, viral resistance to current drugs has drastically increased. Hence, there is a pressing need to design potent broad-spectrum antiviral agents to treat a variety of viral infections and overcome viral resistance. Covalent inhibitors have the potential to achieve both goals owing to their biochemical efficiency, prolonged duration of action, and the capability to inhibit shallow, solvent-exposed substrate-binding domains. In this chapter, we review the structures, activities, and inhibition mechanisms of covalent inhibitors against severe acute respiratory syndrome coronavirus 2, dengue virus, enterovirus, hepatitis C virus, human immunodeficiency virus, and influenza viruses. We also discuss the application of in silico study in covalent inhibitor design.

Keywords: Activities; Covalent antiviral agents; In silico study; Mechanisms; Structures.

PubMed Disclaimer

References

    1. De Wispelaere M, Carocci M, Liang Y et al (2017) Discovery of host-targeted covalent inhibitors of dengue virus. Antiviral Res 139:171–179 - PubMed - DOI
    1. Gurevich EV, Gurevich VV (2014) Therapeutic potential of small molecules and engineered proteins. In: Arrestins-pharmacology and therapeutic potential. Springer, Cham, pp 1–12 - DOI
    1. Bauer RA (2015) Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies. Drug Discov Today 20:1061–1073 - PubMed - DOI
    1. Krippendorff B-F, Neuhaus R, Lienau P et al (2009) Mechanism-based inhibition: deriving KI and kinact directly from time-dependent IC50 values. J Biomol Screen 14:913–923 - PubMed - DOI
    1. Noe MC, Gilbert AM (2012) Targeted covalent enzyme inhibitors. In: Annual reports in medicinal chemistry. Elsevier, Amsterdam, pp 413–439

Substances

LinkOut - more resources